RECRUITING

EUS RFA for Treatment of Pancreatic Ductal Adenocarcinoma (PDAC)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a single arm study in the treatment of pancreatic ductal adenocarcinoma (PDAC). The investigators propose to test the tolerability of chemotherapy plus endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) using the RF Electrode in patients receiving palliative second or third line therapy for unresectable non-metastatic pancreatic cancer.

Official Title

Phase I Pilot Study of Endoscopic Ultrasound Guided RFA in Advanced Pancreatic Cancer

Quick Facts

Study Start:2023-03-31
Study Completion:2026-03
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05723107

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosed and histologically confirmed PDAC by biopsy
  2. * Axial CT scan or MRI consistent with PDAC with at least 1 cm in greatest diameter
  3. * ECOG performance status 0-2
  4. * Patients with locally advanced PDAC, who have not responded or progressed on first line chemotherapy, are deemed not resectable based on multidisciplinary review, and show no evidence of distant metastasis
  5. * Lesions between 1 - 4cm in size
  1. * Patients that show evidence of distant metastasis
  2. * Endoscopically non-accessible mass
  3. * Pregnant patients
  4. * Inability to provide informed consent
  5. * Lesions \<1cm, or \>4cm in greatest diameter

Contacts and Locations

Study Contact

Tamas A. Gonda, MD
CONTACT
212-263-3095
Tamas.Gonda@nyulangone.org
Emil Agarunov
CONTACT
212-263-3095
Emil.agarunov@nyulangone.org

Principal Investigator

Tamas A. Gonda, MD
PRINCIPAL_INVESTIGATOR
NYU Langone Health

Study Locations (Sites)

Tisch Hospital
New York, New York, 10016
United States

Collaborators and Investigators

Sponsor: NYU Langone Health

  • Tamas A. Gonda, MD, PRINCIPAL_INVESTIGATOR, NYU Langone Health

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-03-31
Study Completion Date2026-03

Study Record Updates

Study Start Date2023-03-31
Study Completion Date2026-03

Terms related to this study

Additional Relevant MeSH Terms

  • Pancreatic Cancer